EORTC Presentations at ASCO 2015 in Chicago

The EORTC will present six abstracts at the ASCO 2015 Annual Meeting which will be held 29 May – 02 June 2015 in Chicago, Illinois. Two abstracts will be presented in Oral Abstract Sessions and four in General Poster Sessions.

Oral Abstract Sessions

Citation: J Clin Oncol 33, 2015 (suppl; abstr 2006)
Session: Central Nervous System Tumors
Time: Tuesday June 2, 8:00 AM to 11:00 AM
Location: S404

Brigitta G. Baumert, Monika Hegi, Warren P. Mason, Gail Ryan, Khê Hoang-Xuan, Jacoline E. Bromberg, Martin van den Bent, Mohamed Ben Hassel, Christine Marosi, Alba A. Brandes, Wolfgang Wick, Jeremy Rees, Andreas von Deimling, Christian Hartmann, Johan M Kros, Denis A. Lacombe, Thierry Gorlia, David Capper, Sebastian Kurscheid, Roger Stupp
Radiotherapy in relation to temozolomide: Subgroup analysis of molecular markers of the randomized phase III study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) in patients with a high risk low-grade glioma

Citation: J Clin Oncol 33, 2015 (suppl; abstr 3501)
Session: Gastrointestinal (Colorectal) Cancer
Time: Saturday May 30, 3:00 PM to 6:00 PM
Location: E Hall D2

T. Ruers, C. Punt, F. Van Coevorden, J.P.E.N Pierie, I. Borel-Rinkes, J.A. Ledermann, G. Poston, W. Bechstein, M.A. Lentz, M. Mauer, E. Van Cutsem, M. P. Lutz, B. Nordlinger
Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): Long-term Survival results of a randomised phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC)

General Posters Sessions

Citation: J Clin Oncol 33, 2015 (suppl; abstr 10542)
Session: Sarcoma
Time: Sunday May 31, 8:00 AM to 11:30 AM
Location: S Hall A

Patrick Schoffski, Agnieszka Wozniak, Silvia Stacchiotti, Piotr Rutkowski, Maria Debiec-Rychter, Raf Sciot, Jean-Yves Blay, Lars Lindner, Sandra J. Strauss, David Alan Anthoney, Michael Gordon Leahy, Peter Reichardt, Sandrine Marreaud, Sandra Collette, Jonathan Steuve, Tiana Raveloarivahy, Sebastian Bauer
Activity of crizotinib (XalkoriR, C) in patients (pts) with clear cell sarcoma (CCSA) in EORTC Phase II trial 90101 “CREATE”

Citation: J Clin Oncol 33, 2015 (suppl; abstr 10547)
Session: Sarcoma
Time: Sunday May 31, 8:00 AM to 11:30 AM
Location: S Hall A

Marion Savina, Saskia Litière, Nicolas Penel, Virginie Rondeau Sr., Tomasz Burzykowski, Maud Toulmonde, Antoine Italiano, Simone Mathoulin-Pélissier, Carine A. Bellera
Surrogate properties of survival endpoints in metastatic soft-tissue sarcoma: a meta-analysis.

Citation: J Clin Oncol 33, 2015 (suppl; abstr 10544)
Session: Sarcoma
Time: Sunday May 31, 8:00 AM to 11:30 AM
Location: S Hall A

Stefan Sleijfer, Elisa Rizzo, Saskia Litière, Ron H.J. Mathijssen, Ian Robert Judson, Hans Gelderblom, Antoine Italiano, Winette T.A. Van Der Graaf, Alessandro Gronchi
Association of hematological toxicity (tox) and outcome to doxorubicin (DOX) in advanced soft tissue sarcoma (STS); a retrospective analysis of the EORTC-Soft Tissue and Bone Sarcoma Group database.

Citation: J Clin Oncol 33, 2015 (suppl; abstr 6061)
Session: Head and Neck Cancer
Time: Saturday May 30, 1:15 PM to 4:45 PM
Location: S Hall A       

Amanda Psyrri, Catherine Fortpied, George Koutsodontis, Margaritis Avgeris, Jessica Menis, Leslie Herman, Livia Giurgea, Eva Remenar, Johannes Albertus Langendijk, Ahmad Awada, Pieter H. M. De Mulder, Heinz Roland Kienzer, Marian Degardin, Athanassios Kotsinas, Sjoukje Oosting, Vincent Gregoire, Lisa F. Licitra, Jan B. Vermorken
Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-Fluorouracil with or without docetaxel: retrospective analysis of EORTC 24971 study.